Peer-reviewed research, protocol guides, and clinical insights from the frontier of peptide science. Written for practitioners, researchers, and informed individuals.
FEATURED RESEARCH
How a 15-amino-acid sequence derived from gastric juice protein has become one of the most studied regenerative peptides in modern sports medicine.
Body Protection Compound-157 operates through a cascade of molecular mechanisms that accelerate wound healing, tendon repair, and gut lining restoration. Its unique ability to upregulate growth hormone receptors locally — without systemic GH elevation — has made it a subject of intense clinical interest.
Read full articleBPC
157
LATEST ARTICLES
The discovery that biological age — measured by DNA methylation signatures — can diverge substantially from chronological age has opened new frontiers. Peptide bioregulators, originally developed in the Soviet era by Professor Vladimir Khavinson, are now being evaluated through the lens of modern epigenetics.
The SUSTAIN-6 and SELECT trials demonstrated that semaglutide reduces major adverse cardiovascular events by 20% in high-risk populations. The mechanisms extend beyond glycaemic control — including direct effects on endothelial function, inflammation, and plaque stability.
GHK-Cu (glycine-histidine-lysine-copper) was first identified in human plasma in 1973. Levels peak in early adulthood and fall sharply after age 60 — mirroring the decline in skin quality seen across that period. Topical and systemic administration has shown consistent upregulation of collagen I, collagen III, and elastin.
The emerging science of peptide synergy suggests that carefully designed combinations — such as BPC-157 with TB-500, or Ipamorelin with CJC-1295 without DAC — produce measurably different results than equivalent doses of either compound alone. Understanding receptor cross-talk is essential to protocol design.
Thymosin beta-4 is among the most abundant intracellular peptides in mammals. Its principal role involves sequestering actin monomers and facilitating cell migration to sites of injury. TB-500, the active fragment (amino acids 17–23), retains this activity while improving bioavailability.
New research, protocol guides, and clinical insights — delivered to your inbox monthly.
Subscribe to the journal